Compare AbbVie Inc (ABBV) vs British American Tobacco PLC (BTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs British American Tobacco PLC — how do they compare? AbbVie Inc trades at $250.35 (market cap $438.19B), while British American Tobacco PLC trades at $56.92 (market cap $122.96B). The key difference: AbbVie Inc is far larger — about 3.6× British American Tobacco PLC's market cap, and British American Tobacco PLC pays the higher dividend (5.85%). Which is the better fit depends on your goals.
| ABBV | BTI | |
|---|---|---|
Market Cap | $438.19B | $122.96B |
Sector | Health | Consumer Staples |
52-Week High | $263.58 | $66.70 |
52-Week Low | $197.38 | $50.39 |
Enterprise Value | $502.45B | $166.84B |
Dividend Yield | 2.79% | 5.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.
Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.
BTI trades at $59.33, up 1.02% today, with a bearish technical signal but strong fundamentals including a P/E of 15.15, net income margin of 24.99%, and consistent earnings beats. Recent news highlights growth in next-generation products like Velo, though restructuring and regulatory pressures persist.
The outlook is mixed: valuation appears attractive with a 5%+ dividend yield, but declining operating cash flow and bearish technicals suggest near-term headwinds. Risks include regulatory scrutiny and combustible product declines, while analyst consensus leans bullish with 12 buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →
